ASDS 2024: Results From DecisionDx-Melanoma and DecisionDx-SCC Help Guide Skin Cancer Treatment Decisions
Castle’s DecisionDx-Melanoma and DecisionDx-SCC tests can guide risk-aligned treatment decisions, including sentinel lymph node biopsy (SLNB) for patients with melanoma and surveillance imaging for those with cutaneous squamous cell carcinoma (cSCC), according to data presented in two video abstracts at the 2024 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Orlando, FL. DecisionDx-Melanoma is […]